The first phase of clinical trials (NCT02480439, NCT02684396, NCT02430870) regarding the possibility of using the PDE4 inhibitor-TAK-648/Takeda in type 2 diabetes were completed in 2015. The gene discussed is PDE4A; the disease is type 2 diabetes mellitus.